1. Home
  2. BUSE vs AGIO Comparison

BUSE vs AGIO Comparison

Compare BUSE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Busey Corporation

BUSE

First Busey Corporation

HOLD

Current Price

$26.61

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.25

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUSE
AGIO
Founded
1868
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
BUSE
AGIO
Price
$26.61
$27.25
Analyst Decision
Buy
Buy
Analyst Count
6
8
Target Price
$27.17
$38.88
AVG Volume (30 Days)
450.0K
1.3M
Earning Date
04-28-2026
04-29-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
N/A
EPS
1.47
N/A
Revenue
$719,584,000.00
$43,011,000.00
Revenue This Year
$23.84
$76.75
Revenue Next Year
$3.82
$170.73
P/E Ratio
$17.83
N/A
Revenue Growth
55.66
N/A
52 Week Low
$21.41
$22.24
52 Week High
$27.65
$46.00

Technical Indicators

Market Signals
Indicator
BUSE
AGIO
Relative Strength Index (RSI) 54.01 43.00
Support Level $23.57 $26.03
Resistance Level $27.31 $29.69
Average True Range (ATR) 0.60 1.36
MACD -0.05 -0.19
Stochastic Oscillator 57.05 25.72

Price Performance

Historical Comparison
BUSE
AGIO

About BUSE First Busey Corporation

First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: